Skip to main content
SpringerLink
Log in

Pharmacotherapeutic Follow-up and Pharmacogenetics of CYP2C9 and CYP3A4 in Antihypertensive Therapy: A Pilot Study in a Community Pharmacy

  • Pharmacotherapy
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

No pharmacogenetic studies have yet been conducted in community pharmacies, despite pharmacogenetics being an emerging discipline. Pharmacotherapeutic follow-up (PFU) was performed for 6 months in 37 patients receiving antihypertensive treatment, and they were genotyped for variant alleles *2 and *3 in the CYP2C9 gene and *1B in CYP3A4. Systolic blood pressure, cardiovascular risk, and adherence improved with PFU. Most of the interactions between drugs were represented by concurrent administration of statins and calcium channel blockers, which both use CYP3A4 for their metabolism. Heterozygotic patients for the CYP2C9*2 allele showed higher mean heart rate values after PFU than homozygous patients (73.4 ± 10.0 pulse/min vs 66.2 ± 10.6 pulse/min, respectively; P =.048). Carriers of CYP2C9*2 showed a tendency to less frequent negative outcomes associated with medication due to inefficacy than homozygous patients (50% vs 78.9%, respectively; P =.072). Pharmacogenetics and PFU can be used in community pharmacies to carry out a more exhaustive study of medication in hypertensive outpatients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Materson BJ. Variability in response to antihypertensive drugs. Am J Med. 2007;120:S10–S20.

    Article  CAS  Google Scholar 

  2. Chialda L, Griffith LS. Prospective use of CYP pharmacogenetics and medication analysis to facilitate improved therapy: a pilot study. Per Med. 2008;5:37–45.

    Article  CAS  Google Scholar 

  3. King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004;14:813–822.

    Article  CAS  Google Scholar 

  4. Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun. 2005;338:299–305.

    Article  Google Scholar 

  5. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008;9:738–784.

    Article  CAS  Google Scholar 

  6. Rodríguez Arcas MJ, García-Jiménez E, Martínez-Martínez F, Conesa-Zamora P. Role of CYP450 in pharmacokinetics and pharmacogenetics of antihypertensive drugs. Farm Hosp. 2011;35:84–92.

    Article  Google Scholar 

  7. Marteau JB, Gambier N, Jeannesson E, Siest G, Visvikis-Siest S. Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. Per Med. 2007;4:393–412.

    Article  CAS  Google Scholar 

  8. Amariles P, Sabater-Hernández D, García-Jiménez E, et al. Effectiveness of Dader method for pharmaceutical care on control of blood pressure and total cholesterol in outpatients with cardiovascular disease or cardiovascular risk: EMDADER-CV randomized controlled trial. J Manag Care Pharm. 2012;18:311–323.

    PubMed  Google Scholar 

  9. Pharmaceutical Care Research Group, University of Granada (Spain). Pharmacotherapy follow-up: the Dader method [in Spanish]. 3rd rev. Pharmacy Practice. 2006; 4(1):44–53. Available at: http://scielo.isciii.es/pdf/pharmacy/v4n1/giaf.pdf. Accessed April 9, 2012.

    Google Scholar 

  10. Committee of Consensus. Third consensus of Granada on drug-related problems (DRP) and negative outcomes associated with medication (NOM). Ars Pharm. 2007;48(1):5–17. Available at: http://farmacia.ugr.es/ars/ars_web/ProjectARS/pdf/374.pdf. Accessed April 9, 2012.

    Google Scholar 

  11. Morisky DE, Green LW, Levine AM. Concurrent and predictor validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.

    Article  CAS  Google Scholar 

  12. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.

    Article  CAS  Google Scholar 

  13. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hyperten. 2009;27:2121–2158.

    Article  CAS  Google Scholar 

  14. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphism in Portugal. Pharmacogenomics. 2007;8:703–712.

    Article  CAS  Google Scholar 

  15. Crecenti A, Mas S, Gassó P, Baiget M, Bernardo M, Lafuente A. Simultaneous genotyping of CYP2D6 *3, *4, *5 y *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Clin Exp Pharmacol Physiol. 2007;34:992–997.

    Article  Google Scholar 

  16. Padgett L, O’Connor S, Roederer M, McLeod H, Ferreri S. Pharmacogenomics in a community pharmacy: ACT now. J Am Pharm Assoc (2003). 2011;51:189–193.

    Article  Google Scholar 

  17. Topol EJ. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress? Sci Transl Med. 2010;2:44cm22.

    Google Scholar 

  18. O’Connor SK, Ferreri SP, Michaels NM, et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics. 2012;13:955–962.

    Article  Google Scholar 

  19. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci. 2009;31:158–164.

    Article  Google Scholar 

  20. Medrano MJ, Cerrato E, Boix R, Delgado-Rodrŕguez M. Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies. Med Clin (Barc). 2005;124:606–612.

    Article  Google Scholar 

  21. Armor BL, Britton ML, Dennis VC, Letassy NA. A review of pharmacist contributions to diabetes care in the United States. J Pharm Pract. 2010;23:250–264.

    Article  Google Scholar 

  22. Robinson JD, Segal R, Lopez LM, Doty RE. Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practice. Ann Pharmacother. 2010;44:88–96.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physics and Chemistry, Pharmaceutical Care Research Group, Granada University, Granada, Spain

    María Jesús Rodríguez-Arcas MSc, Emilio García-Jiménez PharmD, Aurora Montesinos-Hernández MSc & Fernando Martínez-Martínez PharmD

  2. Department of Pathology, Molecular Pathology and Pharmacogenetics Group, Santa Lucia University General Hospital, C/Mezquita s/n, 30202, Cartagena, Spain

    Pablo Conesa-Zamora PharmD

Authors
  1. María Jesús Rodríguez-Arcas MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilio García-Jiménez PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aurora Montesinos-Hernández MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fernando Martínez-Martínez PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pablo Conesa-Zamora PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pablo Conesa-Zamora PharmD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodríguez-Arcas, M.J., García-Jiménez, E., Montesinos-Hernández, A. et al. Pharmacotherapeutic Follow-up and Pharmacogenetics of CYP2C9 and CYP3A4 in Antihypertensive Therapy: A Pilot Study in a Community Pharmacy. Ther Innov Regul Sci 47, 489–494 (2013). https://doi.org/10.1177/2168479013492736

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479013492736

Keywords

Search

Navigation